ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................*JBDM Ver 1.7.2 (20 November 2019) - 2999001/03261678CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120210317W173deBibliographieenBibliographyfrBibliographieEP16739870.0201601222017071020190723enenen201562107210 P20150123US2021031720211120180103201801202011112020462020100620210317202111A61K 47/50 20170101AFI20200305BHEP A61P 35/00 20060101ALI20200305BHEP C07K 16/30 20060101ALI20200305BHEP C07K 19/00 20060101ALI20200305BHEP C12N 9/80 20060101ALI20200305BHEP C12N 9/96 20060101ALI20200305BHEP A61K 39/395 20060101ALI20200305BHEP C07K 16/28 20060101ALI20200305BHEP A61K 47/68 20170101ALI20200305BHEP A61K 47/64 20170101ALI20200305BHEP deANTIKÖRPER-UREASE-KONJUGATE FÜR THERAPEUTISCHE ZWECKEenANTIBODY-UREASE CONJUGATES FOR THERAPEUTIC PURPOSESfrCONJUGUÉS ANTICORPS-URÉASE POUR DES FINS THÉRAPEUTIQUESEP-A1- 0 824 019WO-A1-97/15316WO-A1-2004/009112WO-A1-2013/185215WO-A1-2014/165985CA-A1- 2 130 072CA-A1- 2 492 472CA-A1- 2 877 505CA-A1- 2 908 475US-A- 4 762 707Heman Chao ET AL: "Development of an alkalizing antibody-enzyme conjugate for NSCLC treatment that is in Phase I clinical testing Preclinical Studies Abstract Background Starting Dose Derivations Acknowledgement", L-DOS47 PRESENTATION AT AACR 2013 ANNUAL MEETING, 5 April 2013 (2013-04-05), XP055285609, Retrieved from the Internet: URL:http://www.helixbiopharma.com/wp-conte nt/uploads/2014/02/Helix-BioPharma-AACR.pd f [retrieved on 2016-07-04]HELIX BIOPHARMA: "L-DOS47: Single domain antibody conjugated anticancer therapy", BIT'S 5TH ANNUAL INTERNATION CONGRESS OF ANTIBODIES, , 1 January 2013 (2013-01-01), pages 1-35, XP009505019, Retrieved from the Internet: URL:http://www.helixbiopharma.com/wp-conte nt/uploads/2014/02/LDOS47-ICA-2013-HZ-.pdfCHAO H: "DOS47 - Killing cancer by altering the tumor microenvironment", DRUG DELIVERY TECHNOLOGY, DRUG DELIVERY TECHNOLOGY, LLC, US, vol. 11, no. 1, 1 January 2011 (2011-01-01), pages 68-72, XP002763192, ISSN: 1537-2898CHANDLER H M ET AL: "An investigation of the use of urease-antibody conjugates in enzyme immunoassays", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 53, no. 2, 17 September 1982 (1982-09-17), pages 187-194, XP023900599, ISSN: 0022-1759, DOI: 10.1016/0022-1759(82)90140-5 [retrieved on 1982-09-17]Sigma: "ANTI-MOUSE IgG (WHOLE MOLECULE) UREASE CONJUGATE", , 6 January 2006 (2006-01-06), pages 1-1, XP055517511, Retrieved from the Internet: URL:https://www.sigmaaldrich.com/content/d am/sigma-aldrich/docs/Sigma/Datasheet/8/u1 004dat.pdf [retrieved on 2018-10-22]MEYERHOFF M E ET AL: "Electrode-based enzyme immunoassays using urease conjugates", ANALYTICAL BIOCHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 95, no. 2, 1 June 1979 (1979-06-01), pages 483-493, XP024827776, ISSN: 0003-2697, DOI: 10.1016/0003-2697(79)90760-7 [retrieved on 1979-06-01]AN-PING DENG ET AL: "Application of a polyaniline based ammonium sensor for the amperometric immunoassay of a urease conjugated Tal 1 protein", ANALYTICA CHIMICA ACTA, vol. 461, no. 1, 1 June 2002 (2002-06-01), pages 49-55, XP055517531, AMSTERDAM, NL ISSN: 0003-2670, DOI: 10.1016/S0003-2670(02)00251-9TIAN ET AL.: 'Production and characterization of a camelid single domain antibody-urease enzyme conjugate for the treatment of cancer' BIOCONJUGATE CHEMISTRY vol. 26, no. 6, 17 June 2015, pages 1144 - 1155, XP055271801 DOI: 10.1021/ACS.BIOCONJCHEM.5B00237CHAO ET AL.: 'Development of an alkalizing antibody-enzyme conjugate for NSCLC treatment that is in Phase I clinical testing' L-DOS47 PRESENTATION AT AACR 2013 ANNUAL MEETING, [Online] 05 April 2013, pages 1 - 1, XP055285609 Retrieved from the Internet: <URL:HTTP://WWW.HELIXBIOPHARMA.COM/WP-CONTE NT/UPLOADS/2014/02/HELIX-BIOPHARMA-AACR.PDF >HELIX BIOPHARMA: 'L-DOS47: Single domain antibody conjugated anticancer therapy' BIT'S 5TH ANNUAL INTERNATION CONGRESS OF ANTIBODIES, [Online] 2013, XP009505019 Retrieved from the Internet: <URL:WWW.HELIXBIOPHARMA.COM/WP-CONTENT/UPLO ADS/2014/02/LDOS47-ICA-2013-HZ.PDF>CHAO: 'DOS47 - Killing cancer by altering the tumor microenvironment' DRUG DEVELOPMENT AND DELIVERY vol. 11, no. 1, 01 January 2011, pages 68 - 72, XP002763192WONG ET AL.: 'Urease-induced alkalinization of extracellular pH and its antitumor activity in human breast and lung cancers' JOURNAL OF EXPERIMENTAL THERAPEUTICS AND ONCOLOGY vol. 5, no. 2, 01 January 2005, pages 93 - 99, XP00914742020181102CHAO, Heman5 Hogaboom AvenueAurora, Ontario L4G 0E5CAWONG, Wah Yau8812-188 St. NWEdmonton, Alberta T5T 5Z8CATIAN, Baomin4325 McMullen Way SWEdmonton, Alberta T6W 1N5CAGASPAR, Kimberly Jayne11-416 23rd St. EastSaskatoon, Saskatchewan S7K 0J7CAKUMAR, Praveen115 Fawcett CrescentSaskatoon, Saskatchewan S7T 0G1CAHelix Biopharma Corp.101735936AXH/84455EP19120 Leslie Street Suite 205Richmond Hill, ON L4B 3J9CAHutter, Antonet al101053823Venner Shipley LLP 5 Stirling House Stirling Road The Surrey Research ParkGuildford GU2 7RFGBALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTRIB201605034220160122enWO201611690720160728201630